AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00568217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diclofenac, Paracetamol, Ibuprofen
Description: Immediately if temperature > 38 degree Celsius, diclofenac suppository 1,5 mg/kg once or placebo suppository After eight hours, if temperature still \< 38 degree Celsius, acetaminophen mixture 15 mg/kg up to four times a day, or ibuprofen mixture 10 mg/kg up to four times a day, or placebo mixture up to four times a day as long as temperature \< 38 degree Celsius
Study NCT02508103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intranasal Oxytocin spray (40 IU, 3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
Study NCT05724238 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Traditional Herbal Supplements (Kuan Sin Yin)
Description: Astragalus-based Kuan Sin Yin
Study NCT05724238 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo starch powder with 10% Kuan Sin Yin
Study NCT01898377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate, Mycophenolate mofetil
Study NCT02508103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intranasal Placebo spray (3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
Study NCT02906579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Study NCT02906579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-1973
Study NCT03422575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120Mg Film-coated Tablet
Description: One tablet of the Test drug was given orally (swallowed with 200 mL of water, without chewing), after an overnight fast, and after fasting (pre-dose) blood-sampling.
Study NCT03422575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arcoxia® 120 mg Film-coated tablet (Frosst Iberica S.A., Spain for Merck Sharp & Dohme (Australia) Pty Limited, Australia, registered by PT. Schering-Plough Indonesia Tbk)
Description: One tablet of the Reference drug was given orally (swallowed with 200 mL of water, without chewing), after an overnight fast, and after fasting (pre-dose) blood-sampling.
Study NCT05721547 — intervention group
Intervention type: OTHER
Intervention: Assessment
Description: Assessment
Study NCT04209569 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Impact and Positive Practice Circle (NIPP)
Description: GOAL's NIPP approach is a gendered, grass-roots SBC approach, tackling a package of underlying behavioral determinants of malnutrition, irrespective of the particular manifestation. The approach is multi-sectoral in nature. It also has a strong monitoring, evaluation and adaptive learning component by design. The intervention approach (based on GOAL's NIPP approach) involves the creation of community, male and female circles in each community with messaging and activities targeted towards the three groups in varying intensities. While the male and female circles meet 2-3 times per week for a maximum period of 12 weeks while the community circles will meet for approximately three hours at any one time over a period of 2-7 days. (See GOAL NIPP Implementation Guidelines)
Study NCT04209569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Impact and Positive Practice Circle (NIPP)
Description: GOAL's NIPP approach is a gendered, grass-roots SBC approach, tackling a package of underlying behavioral determinants of malnutrition, irrespective of the particular manifestation. The approach is multi-sectoral in nature. It also has a strong monitoring, evaluation and adaptive learning component by design. The intervention approach (based on GOAL's NIPP approach) involves the creation of community, male and female circles in each community with messaging and activities targeted towards the three groups in varying intensities. While the male and female circles meet 2-3 times per week for a maximum period of 12 weeks while the community circles will meet for approximately three hours at any one time over a period of 2-7 days. (See GOAL NIPP Implementation Guidelines)
Study NCT00776906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advance® 18PTX® Balloon Catheter
Study NCT00776906 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Advance® 18LP Balloon Catheter
Study NCT04371120 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BICS Q
Description: assess perceived self-efficacy (PSE) regarding a person's brain injury and proved responsive to treatment effects in the original BICS study.15-16 Specifically, it measures a person's perceptions about his or her ability to both understand the effects of brain injury, as well as, perceived capability of managing BI-related challenges. As the literature suggests, it is important to utilize a measure that would assess PSE specific to the person's challenge, rather than a general PSE scale.
Study NCT01970254 — intervention group
Intervention type: OTHER
Intervention: Hepatitis B Screening
Description: Undergo 3 HBV screening tests (HbsAg, anti-HBc, and anti-HBs)
Study NCT01970254 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies
Study NCT00890578 — intervention group
Intervention type: PROCEDURE
Intervention: adhesive to suture
Description: surgical closure
Study NCT02330094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications.
Study NCT02330094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications.
Study NCT03805542 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 0.5% Iodophors
Description: Before lithotripsy, 0.5% iodophor 40 ml(depending on the degree of hydronephrosis) was used to perfuse the calculous side pelvis under low pressure for 5 minutes.
Study NCT00540943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit.
Study NCT00540943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be supplied as a single-use 50 milliliter vial containing 100 micrograms of cetuximab as a sterile, preservative-free, injectable liquid at a concentration of 2 milligram per milliliter in phosphate.~buffered saline
Study NCT00540943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan hydrochloride trihydrate is an antineoplastic agent of the topoisomerase I inhibitor class.
Study NCT02211547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epic 10 Diode Laser by Biolase Inc.
Study NCT02211547 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single blind lack of laser treatment (the laser will be positioned and operated as if applying the treatment, but the energy transfer will not take place).
Study NCT02563548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGPH20
Description: PEGPH20 will be administered as an intravenous (IV) infusion as per the dose schedule specified in the arm description.
Study NCT02563548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an IV infusion as per the dose schedule specified in the arm description.
Study NCT00867698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: AST-120
Study NCT00867698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AST-120
Description: AST-120
Study NCT03057847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir
Description: Sofosbuvir/Velpatasvir One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily for 12 weeks in the postpartum period
Study NCT02879383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DMR Procedure
Description: The DMR procedure consists of hydrothermal ablation of the duodenum using the Revita System
Study NCT02879383 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: The sham procedure consists of placing the Revita Catheter into the stomach for 30 minutes and then removing it from the patient.
Study NCT00980642 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Draeger double-sensor
Description: The sensor will be attached to the patient's forehead with adhesive tape, and a small amount of contact gel will be applied between sensor and skin.
Study NCT00980642 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Esophageal stethoscope temperature sensor
Description: Esophageal temperature is measured by sensors incorporated into an esophageal stethoscope during the surgery.
Study NCT00980642 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Foley catheter temperature sensor
Description: Urinary bladder temperature is measured via a sensor incorporated into a Foley catheter during the surgery
Study NCT04392492 — intervention group
Intervention type: DEVICE
Intervention: MANTA vascular closure device
Description: Femoral access site closure using the MANTA closure device
Study NCT02526966 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sample
Description: dosage of anti-hinge region antibodies
Study NCT04211090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens
Study NCT04211090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens
Study NCT04211090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens
Study NCT05209516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral data
Description: Participants will be seated comfortably in front of a cathode ray tube screen, at a distance of 50-70 cm. The refresh rate of the monitor will be kept above 75 Hz to avoid visual fatigue. Participants will be asked to perform an instructed-delay choice reaction-time task in which they will have to choose between a left and right finger response. In this task, we measure the reaction-times and movement times.
Study NCT05209516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral data
Description: Participants will be seated comfortably in front of a cathode ray tube screen, at a distance of 50-70 cm. The refresh rate of the monitor will be kept above 75 Hz to avoid visual fatigue. Participants will be asked to perform an instructed-delay choice reaction-time task in which they will have to choose between a left and right finger response. In this task, we measure the reaction-times and movement times.
Study NCT05209516 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Single-pulse transcranial magnetic stimulation (TMS)
Description: While being comfortably seated in a chair and performing the pre-mentioned task, the participants will undergo single-pulse TMS over both primary motor cortices (M1). In order to guarantee the position of the stimulation coils throughout the testing, participants are asked to wear an EEG cap which will be used to mark various scalp locations. Bipolar surface electrodes, linked to an electromyography (EMG) system, will be placed over one or more muscles of each hand in order to measure the amplitude of motor evoked potentials at various stages of the task. Prior to the placement of each adhesive surface electrode, the skin will be gently swabbed with an alcohol solution.
Study NCT05209516 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Single-pulse transcranial magnetic stimulation (TMS)
Description: While being comfortably seated in a chair and performing the pre-mentioned task, the participants will undergo single-pulse TMS over both primary motor cortices (M1). In order to guarantee the position of the stimulation coils throughout the testing, participants are asked to wear an EEG cap which will be used to mark various scalp locations. Bipolar surface electrodes, linked to an electromyography (EMG) system, will be placed over one or more muscles of each hand in order to measure the amplitude of motor evoked potentials at various stages of the task. Prior to the placement of each adhesive surface electrode, the skin will be gently swabbed with an alcohol solution.
Study NCT05209516 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Montreal Cognitive Assessment (MoCA), Beck Depression Inventory (BDI) II, Scale on impulsive behaviour (UPPS).
Study NCT05209516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Montreal Cognitive Assessment (MoCA), Beck Depression Inventory (BDI) II, Scale on impulsive behaviour (UPPS).
Study NCT05209516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MDS (Movement Disorder Society) UPDRS (Unified Parkinson's Disease Rating Scale) Part 3 (Motor Part)
Description: Specific Parkinson Questionnaire on Clinical motor status
Study NCT04905576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation training
Description: Muscle relaxation training
Study NCT03681899 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: * Socio-demographic data (age, sex, place of residence, and family status, last occupation, existence or not of a primary caregiver (family and / or professional));~* Medical and surgical history (Charlson Comorbidity Scale);~* Assessment of oral/dental condition~* Record of drug treatments (number of oral medications per day, therapeutic class, number of daily intakes);~* Oral treatments intake modalities (galenic breakdown of one or more drugs, usual or occasional, modalities of rupture, person responsible for the drugs, mixing with food / drink);~* Autonomy evaluation (Lawton and Katz scales);~* Mobility assessment (anamnestic evaluation);~* Evaluation of Thyme (GDS 4 items);~* Psycho-behavioral disorders,~* Assessment of swallowing (presence of a diagnosis of dysphagia or suspicion based on anamnestic data).
Study NCT01347593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftizoxime
Description: ceftizoxime (cefizox) injection either after clamping the cord
Study NCT00997347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol
Description: 200 mg oral mifepristone~800 mcg buccal misoprostol or 400 mcg sublingual misoprostol 24-48 hours after mifepristone
Study NCT04905576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Description: Healing Touch (HT) therapy
Study NCT04905576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Study NCT04905576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire administration
Study NCT02816320 — intervention group
Intervention type: OTHER
Intervention: Hospitalization
Description: Patients who were hospitalized in acute care
Study NCT01314027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy with gemcitabine/oxaliplatin
Description: Patients with resectable cytologically proven adenocarinoma of the pancreatic head are randomized to arm A or B.~Patients randomized to arm A receive an 8-week neoadjuvant chemotherapy with gemcitabine/oxaliplatin. Thereafter, surgery is performed if the restaging does not reveal a contraindication. Finally, all patients receive adjuvant gemcitabine for six months.
Study NCT01314027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant chemotherapy with gemcitabine
Description: Patients randomized to arm B undergo surgery and receive the same adjuvant treatment as in arm A.
Study NCT04905576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ancillary studies
Description: Subjects in all groups will give 4 blood samples during the study
Study NCT04905576 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ancillary studies
Description: Subjects in all groups will give 4 blood samples during the study
Study NCT03504722 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RESCUE
Description: RESCUE is designed to adapt to individualized needs based on each veteran's performance. The volunteer training consists of weekly sessions lasting 90 minutes each and occurring at area SPCA facilities. The logistics of the training sessions will be facilitated by study staff, with SPCA animal behaviorists and professionals conducting the training program identical to the program that they use for their general volunteer training. During volunteer sessions, the veteran learns behavioral techniques for training non-aggressive dogs through didactic instruction followed by demonstration and supervised practice. The animal socialization component of the RESCUE volunteer sessions are comprised of the SPCAs current training program, which is designed developmentally such that early training focuses on general topics (safety, basic handling skills) and later training builds on previously learned skills through successive approximation within each individual's zone of proximal development.
Study NCT02198508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DFX(Deferasirox)
Study NCT02198508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFX(Deferasirox)
Study NCT02198508 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DFP(Deferiprone)
Study NCT02198508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFP(Deferiprone)
Study NCT03558685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss diet
Description: Nutritional recommendation consisted of moderate caloric restriction, set at 25% to 30% less than calories needed for resting metabolic rate. We applied a high protein Mediterranean diet with the following food group distribution: 30% as protein (> 0.8 g/kg/d); 40% as carbohydrates with medium/low glycemic index; 30% as fat (≥10% monounsaturated fatty acid, ≤7% saturated fatty acid, no trans fats, and 1.6 g omega-3 for men and 1.1 g omega-3 for women). Diet was rich in olive oil, fish, chicken, nuts, white milk products, fruits, and vegetables but low in artificial sugars, commercial sweets, pastries, butter, margarine, and red meat. Dietary fiber content ≥25 g/day
Study NCT01176123 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia
Study NCT01176123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia
Study NCT04034511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medically-tailored meal delivery and medical nutrition therapy
Description: Home-delivered, medically-tailored meals for 3 months combined with monthly individual medical nutrition therapy sessions for 6 months
Study NCT03671512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Periodontal Structure Repair (PSR)
Description: Following local anesthesia, initial pocket preparation will be done by bur abrasion utilizing specially designed burs to plane the root surface and remove the inner lining of the pocket. Following bur abrasion, thin strips of gauze sponge are placed into the created space. After removing the gauze strips, PSR is inserted to fill the spaces beginning at the pocket bottom. The final step is placing a layer of cyanoacrylate on both the gingival margin and tooth supragingivally.
Study NCT03671512 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Root Planing
Description: Ultrasonics and hand instruments are used to remove any subgingival deposits on the roots. Standard instruments and standard application are used. Visual or instrument tactile inspection is used to verify the roots are hard-smooth and have been adequately cleaned.
Study NCT05054205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational İnterviewing
Description: The most current version of Motivational İnterviewing (MI) is described in detail in Miller and Rollnick (2013) Motivational Interviewing: Helping people to change (3rd edition). Key qualities include:~MI is a guiding style of communication, that sits between following (good listening) and directing (giving information and advice).~MI is designed to empower people to change by drawing out their own meaning, importance and capacity for change.~MI is based on a respectful and curious way of being with people that facilitates the natural process of change and honors client autonomy.
Study NCT04069728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Explanation with 3D printed fistula model
Description: Explanation of fistula and surgery using a 3D printed model of an anal fistula that depicts the anatomy of the anal canal, the path of the anal fistula and its relation to anatomic structures.